126 related articles for article (PubMed ID: 36194314)
1. Identification and Exploration of Serine Peptidase Inhibitor Kazal Type I (SPINK1) as a Potential Biomarker Correlated with the Progression of Non-Small Cell Lung Cancer.
Li D; Zhang X; Ding Z; Ai R; Shi L; Wang Z; He Q; Dong Y; Zhu Y; Ouyang W; He Y
Cell Biochem Biophys; 2022 Dec; 80(4):807-818. PubMed ID: 36194314
[TBL] [Abstract][Full Text] [Related]
2. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
[TBL] [Abstract][Full Text] [Related]
3. Serine protease inhibitor Kazal type 1 (SPINK1) promotes proliferation, migration, invasion and radiation resistance in rectal cancer patients receiving concurrent chemoradiotherapy: a potential target for precision medicine.
Chen YT; Tseng TT; Tsai HP; Kuo SH; Huang MY; Wang JY; Chai CY
Hum Cell; 2022 Nov; 35(6):1912-1927. PubMed ID: 36053457
[TBL] [Abstract][Full Text] [Related]
4. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
Front Immunol; 2022; 13():923031. PubMed ID: 35924241
[TBL] [Abstract][Full Text] [Related]
5. SPINK1 promotes cell growth and metastasis of lung adenocarcinoma and acts as a novel prognostic biomarker.
Xu L; Lu C; Huang Y; Zhou J; Wang X; Liu C; Chen J; Le H
BMB Rep; 2018 Dec; 51(12):648-653. PubMed ID: 30545439
[TBL] [Abstract][Full Text] [Related]
6. Functional Roles of SPINK1 in Cancers.
Lin TC
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33916984
[TBL] [Abstract][Full Text] [Related]
7. Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.
Ying HY; Gong CJ; Feng Y; Jing DD; Lu LG
J Dig Dis; 2017 Jun; 18(6):349-358. PubMed ID: 28544403
[TBL] [Abstract][Full Text] [Related]
8. Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma.
Shek FH; Luo R; Lam BYH; Sung WK; Lam TW; Luk JM; Leung MS; Chan KT; Wang HK; Chan CM; Poon RT; Lee NP
Cell Oncol (Dordr); 2017 Oct; 40(5):443-456. PubMed ID: 28631187
[TBL] [Abstract][Full Text] [Related]
9. Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma.
Mehner C; Miller E; Hockla A; Coban M; Weroha SJ; Radisky DC; Radisky ES
Oncogene; 2020 Oct; 39(42):6606-6618. PubMed ID: 32929152
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 increases expression of serine protease inhibitor Kazal type 1 through STAT3 in colorectal adenocarcinoma.
Räsänen K; Lehtinen E; Nokelainen K; Kuopio T; Hautala L; Itkonen O; Stenman UH; Koistinen H
Mol Carcinog; 2016 Dec; 55(12):2010-2023. PubMed ID: 26663388
[TBL] [Abstract][Full Text] [Related]
11. Serine peptidase inhibitor Kazal type I (SPINK1) promotes BRL-3A cell proliferation via p38, ERK, and JNK pathways.
Chang C; Zhao W; Luo Y; Xi L; Chen S; Zhao C; Wang G; Guo J; Xu C
Cell Biochem Funct; 2017 Aug; 35(6):339-348. PubMed ID: 28845526
[TBL] [Abstract][Full Text] [Related]
12. SPINK1 is a prognosis predicting factor of non-small cell lung cancer and regulates redox homeostasis.
Guo M; Zhou X; Han X; Zhang Y; Jiang L
Oncol Lett; 2019 Dec; 18(6):6899-6908. PubMed ID: 31788129
[TBL] [Abstract][Full Text] [Related]
13. TMEM100 induces cell death in non‑small cell lung cancer via the activation of autophagy and apoptosis.
He Q; Dong Y; Zhu Y; Ding Z; Zhang X; Wang Z; Ai R; He Y
Oncol Rep; 2021 May; 45(5):. PubMed ID: 34184748
[TBL] [Abstract][Full Text] [Related]
14. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
15. miR-421 up-regulation by the oleanolic acid derivative K73-03 regulates epigenetically SPINK1 transcription in pancreatic cancer cells leading to metabolic changes and enhanced apoptosis.
Shopit A; Li X; Tang Z; Awsh M; Shobet L; Niu M; Wang H; Mousa H; Alshwmi M; Tesfaldet T; Gamallat Y; Li H; Chu P; Ahmad N; Jamalat Y; Ai J; Qaed E; Almoiliqy M; Wang S; Tang Z
Pharmacol Res; 2020 Nov; 161():105130. PubMed ID: 32818653
[TBL] [Abstract][Full Text] [Related]
16. PDIA6 modulates apoptosis and autophagy of non-small cell lung cancer cells via the MAP4K1/JNK signaling pathway.
Bai Y; Liu X; Qi X; Liu X; Peng F; Li H; Fu H; Pei S; Chen L; Chi X; Zhang L; Zhu X; Song Y; Wang Y; Meng S; Jiang T; Shao S
EBioMedicine; 2019 Apr; 42():311-325. PubMed ID: 30922965
[TBL] [Abstract][Full Text] [Related]
17. High SPINK1 Expression Predicts Poor Prognosis and Promotes Cell Proliferation and Metastasis of Hepatocellular Carcinoma.
Huang K; Xie W; Wang S; Li Q; Wei X; Chen B; Hua Y; Li S; Peng B; Shen S
J Invest Surg; 2021 Sep; 34(9):1011-1020. PubMed ID: 32066292
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B Virus X Protein-Induced Serine Protease Inhibitor Kazal Type 1 Is Associated with the Progression of HBV-Related Diseases.
Zhu C; Han H; Li J; Xu L; Liu F; Wu K; Liu X
Biomed Res Int; 2019; 2019():9321494. PubMed ID: 31240230
[TBL] [Abstract][Full Text] [Related]
19. High expression of serine protease inhibitor kazal type 1 predicts poor prognosis and promotes the progression and invasion of oral tongue squamous cell carcinoma.
Wang S; Sun Y; Shao D; Pan Y; Gao X; Zhao P; Liu Q; Shang G; Shang W; Fu Z; Sun Y
Arch Oral Biol; 2024 May; 164():106003. PubMed ID: 38781741
[TBL] [Abstract][Full Text] [Related]
20. Sirtuin 7 promotes non‑small cell lung cancer progression by facilitating G1/S phase and epithelial‑mesenchymal transition and activating AKT and ERK1/2 signaling.
Zhao Y; Ye X; Chen R; Gao Q; Zhao D; Ling C; Qian Y; Xu C; Tao M; Xie Y
Oncol Rep; 2020 Sep; 44(3):959-972. PubMed ID: 32705247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
